A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects with Stargardt Disease and a Phase 2/3, Randomized, Double masked, and Placebo controlled Study to Evaluate
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Belite Bio (HK) Limited
Start Date
August 29, 2024
End Date
September 14, 2029
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Belite Bio (HK) Limited
Start Date
August 29, 2024
End Date
September 14, 2029